SCHEMBL803737

SCHEMBL803737

COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(=O)OC(C)(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.42
TLR2 O60603 2/20 0.39
TLR1 Q15399 2/20 0.39
SMN1; SMN2 Q16637 3/20 0.37
HPGD P15428 2/20 0.37
HTT P42858 1/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
KDM4E B2RXH2 2/20 0.35
GLA P06280 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
CNR1 P21554 1/20 0.35
PLK1 P53350 3/20 0.34
RECQL P46063 1/20 0.34
CA12 O43570 2/20 0.34
CA1 P00915 2/20 0.34
CA2 P00918 2/20 0.34
CA4 P22748 2/20 0.34
CA9 Q16790 2/20 0.34
CA14 Q9ULX7 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13225385 1.00 TSHR (0.42) TSHRTLR2TLR1SMN1; SMN2HPGD
SCHEMBL29467640 1.00 TSHR (0.42) TSHRTLR2TLR1SMN1; SMN2HPGD
SCHEMBL30748709 0.90 TSHR (0.53) TSHRTLR2TLR1SMN1; SMN2HPGD
SCHEMBL14117979 0.89 TSHR (0.47) TSHRTLR2TLR1SMN1; SMN2HPGD
SCHEMBL25330597 0.88 TLR2 (0.41) TSHRTLR2TLR1SMN1; SMN2MEN1
SCHEMBL25933067 0.88 TLR2 (0.39) TSHRTLR2TLR1MEN1KMT2A
SCHEMBL25933066 0.88 TLR2 (0.39) TLR2TLR1SMN1; SMN2MEN1KMT2A
SCHEMBL25933059 0.88 TLR2 (0.39) TSHRTLR2TLR1MEN1KMT2A
SCHEMBL21611677 0.88 TLR2 (0.41) TSHRTLR2TLR1SMN1; SMN2MEN1
SCHEMBL22388928 0.87 TLR2 (0.38) TSHRTLR2TLR1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8987197-B2 Protease stabilized, pegylated insulin analogues and uses thereof NOVO NORDISK A/S (DK) 2015-03-24 US disclosed
US-20120071402-A1 Protease Stabilized, Pegylated Insulin Analogues NOVO NORDISK A/S (DK) 2012-03-22 US disclosed
US-20110319591-A1 PEGYLATED, EXTENDED INSULINS NOVO NORDISK A/S (DK) 2011-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319591-A1 PEGYLATED, EXTENDED INSULINS IAPP, IGF1R, INSR TSHR 576/4885TLR2 2948/4885TLR1 1650/4885
US-20120071402-A1 Protease Stabilized, Pegylated Insulin Analogues IDE, IAPP, IGFBP4 TSHR 656/4885TLR2 3842/4885TLR1 3549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.